# IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment

> **NCT02268006** · PHASE2 · UNKNOWN · sponsor: **Institute of Oncology Ljubljana** · enrollment: 50 (estimated)

## Conditions studied

- Rectal Carcinoma

## Interventions

- **RADIATION:** IMRT-SIB
- **DRUG:** Capecitabine
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT02268006
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2020-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268006, "IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02268006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*